Oncocyte is a precision diagnostics company dedicated to improving patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey. The company operates in the healthcare diagnostics market, focusing on innovative solutions that empower physicians with bold and advanced diagnostic tools. Oncocyte serves doctors and patients by offering a novel multivariate gene expression test to identify immune checkpoint inhibitor responders and a test to monitor kidney transplant health through the detection of donor-derived cell-free DNA. The business model revolves around developing and commercializing these diagnostic tests, generating revenue through the sale of these tests to healthcare providers and institutions. Oncocyte's laboratory, located in Nashville, TN, holds a CLIA Certificate of Accreditation from the Centers for Medicare and Medicaid Services (CMS), ensuring high standards of quality and reliability in their diagnostic services. The company aims to deliver better patient care today by focusing on tomorrow's diagnostic needs, leveraging advanced molecular biology techniques and next-generation sequencing platforms.

Keywords: precision diagnostics, gene expression test, immune checkpoint inhibitors, kidney transplant monitoring, personalized insights, patient outcomes, healthcare diagnostics, CLIA accredited, molecular biology, next-generation sequencing.